TD 101

Drug Profile

TD 101

Alternative Names: Pachyonychia congenita siRNA; Reveker; sdTD-K6a.513a.12; siRNA sdTD101; TD-K6a.513a.12; TD101

Latest Information Update: 26 Apr 2016

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator TransDerm
  • Developer International Pachyonychia Congenita Consortium; PC Project; TransDerm
  • Class Skin disorder therapies; Small interfering RNA
  • Mechanism of Action RNA interference
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • No development reported Pachyonychia congenita

Most Recent Events

  • 20 Apr 2016 No recent reports on development identified - Preclinical for Pachyonychia congenita in USA (Topical)
  • 17 Jan 2008 Phase-I clinical trials in Pachyonychia congenita in USA (Intradermal)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top